Orthofix Medical Inc. (OFIX) Stock Price & Analysis

Orthofix Medical Inc. (OFIX) closed at USD 7.9 on Monday, November 9, 2026, up 0.38% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 7.87; the Nov 9, 2026 session ranged USD 6.52–8.03 on volume of 2,694,548 shares. Market capitalization is $321.92M, with a 52-week range of USD 6.52–16.42 (NMS). Source: Nexqual, retrieved November 10, 2026 at 13:11 UTC.

Also available as compact Markdown for AI agents: nexqual.com/OFIX.md

Latest Earnings Results (OFIX)

Orthofix Medical Inc. (OFIX) reported Q3 2026 results on Nov 9, 2026, 8:01:00 AM ET: GAAP EPS -$0.15 vs. estimate $0.11 (miss), revenue $207.86M vs. estimate $210.52M (miss). Guidance: Full-year 2026 net sales guidance revised to $825 million to $830 million. Source: SEC 8-K filing. Nexqual published it 63 seconds after release. Read the SEC filing. Full report with estimates: nexqual.com/earnings/2026-11-09/OFIX.

Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.

Key facts (OFIX)

• Last four reported quarters (through Sep 30, 2026): revenue $835M, net income -$45.0M (-5.4% margin), free cash flow -$44.5M (SEC filings).
• Insider open-market sales, last ~7 months: 5 Form 4 filings, $52K; 2 not under a Rule 10b5-1 plan ($47K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 2 Form 4 filings, $2.3M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 12.25 (range 10–14).
• Total return with dividends: 1Y -47.4% vs S&P 500 +11.7%; 5Y -75.7% vs S&P 500 +72.2%.
• Latest earnings report: 2026-11-09 (next date not yet announced).
• Dividend: OFIX paid no cash dividend in the last five years.
• Short interest: 6.63% of float (as of 2026-10-15), 5.6 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OFIX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (OFIX)

P/S 0.4x · EV/EBITDA 14.1x · EV/Sales 0.6x · P/B 0.8x · FCF yield -13.81% · Earnings yield -13.98% · Net debt $136M · EV $457M

Insider sales (SEC Form 4, open-market, last ~7 months) (OFIX)

3 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (OFIX)

2 purchases, $2.3M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (OFIX)

Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 12.25 (low 10, high 14).

Rating changes, last 120 days:

Total return (dividends reinvested) (OFIX)

Dividends (OFIX)

OFIX paid no cash dividend in the last five years.

Short interest (OFIX)

2,391,732 shares sold short, 6.63% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,506,524 shares (-4.6%). Days to cover: 5.6 (short shares ÷ average daily volume).

OFIX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

OFIX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

OFIX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

OFIX company outlook (results filed Nov 9, 2026)

• “(NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance.”
• “Our revised guidance reflects third-quarter performance and the near-term impact of these actions, which are intended to build a stronger foundation for sustainable growth, profitability and cash generation." 1 Spine Fixation is comprised of the Company's Spinal Implants product category, excluding motion preservation product offerings. 1 Financial Results Overview Third Quarter 2026 Net Sa”

Quoted word-for-word from the SEC 8-K results press release.

OFIX analyst estimates and revisions

OFIX options: expected move

30-day implied volatility 69.2% vs 71.9% realized over the last 30 trading days. Put/call ratio (volume) 0.21. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 10, 2026 at 13:11 UTC)

Technical Analysis (OFIX)

Nexqual's technical model rates OFIX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of November 10, 2026 at 13:11 UTC.

Analyst Ratings (OFIX)

Wall Street analysts rate OFIX "Buy" based on 4 analysts, with a mean price target of USD 12.25 (range USD 10–14), per Nexqual as of November 10, 2026 at 13:11 UTC.

Earnings (OFIX)

Recent Earnings History

Source: Nexqual, November 10, 2026 at 13:11 UTC.

Financials & Fundamentals (OFIX)

Source: Nexqual, November 10, 2026 at 13:11 UTC.

Financial Health Score (OFIX)

Nexqual rates Orthofix Medical Inc.'s overall financial health "Mixed" across five dimensions, as of November 10, 2026 at 13:11 UTC.

Ownership (OFIX)

Source: Nexqual, November 10, 2026 at 13:11 UTC.

Leadership (OFIX)

Orthofix Medical Inc. is led by Massimo Calafiore, President, CEO & Director, per Nexqual as of November 10, 2026 at 13:11 UTC.

Major Backers & Investors (OFIX)

Notable institutional backers of Orthofix Medical Inc. include Engine Capital Management, LP, Juniper Investment Company, LLC, Rubric Capital Management LP, according to Nexqual as of November 10, 2026 at 13:11 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, November 10, 2026 at 13:11 UTC.

From Orthofix Medical Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System.
• Examples of our internal fixation devices include Chimaera, AHN, and G-BEAM Fusion Beaming System.
• Most notably, all of our products sold in the U.S. are subject to the Federal Food, Drug, and Cosmetic Act (the "FDCA") and the Public Health Services Act, as implemented and enforced by the FDA.
• The device uses proprietary technology and a wavelength to generate a PEMF signal.

Partnerships

• We receive marketing fees through our collaboration with MTF for Virtuos, Trinity Elite, FiberFuse, and certain other tissues.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to the FCPA and other similar anti-bribery laws, and any violations of such laws could subject us to adverse consequences.
• We and certain of our suppliers may be subject to extensive government regulation that increases our costs and could limit our ability to market or sell our products.
• The approval or clearance by governmental authorities, including the FDA in the U.S., is generally required before any medical devices may be marketed in the U.S. or other countries. We cannot predict whether, in the future, the U.S. or foreign governments may impose regulations that have a material adverse effect on our business, financial condition, results of operations, or cash flows.
• The process of obtaining FDA clearance and approvals to develop and market a medical device can be costly, time-consuming, and subject to the risk that such clearances or approvals will not be granted on a timely basis, if at all.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 10, 2026 at 13:11 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt